Exagen, Inc. (XGN)
7.72
-0.84
(-9.81%)
USD |
NASDAQ |
Oct 16, 16:00
7.64
-0.08
(-1.04%)
After-Hours: 20:00
Exagen Research and Development Expense (Annual) : 6.254M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 6.254M |
| December 31, 2024 | 5.375M |
| December 31, 2023 | 4.865M |
| December 31, 2022 | 9.876M |
| December 31, 2021 | 7.237M |
| December 31, 2020 | 3.568M |
| December 31, 2019 | 2.176M |
| Date | Value |
|---|---|
| December 31, 2018 | 2.125M |
| December 31, 2017 | 1.551M |
| December 31, 2015 | 1.367M |
| December 31, 2014 | 1.287M |
| December 31, 2013 | 0.897M |
| December 31, 2012 | 1.055M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Myriad Genetics, Inc. | 106.80M |
| BioRestorative Therapies, Inc. | 10.09M |
| CareDx, Inc. | 71.43M |
| Natera, Inc. | 624.11M |
| Sera Prognostics, Inc. | 12.35M |